MX361984B - Sales clorhidrato de un compuesto antibiótico. - Google Patents

Sales clorhidrato de un compuesto antibiótico.

Info

Publication number
MX361984B
MX361984B MX2015012170A MX2015012170A MX361984B MX 361984 B MX361984 B MX 361984B MX 2015012170 A MX2015012170 A MX 2015012170A MX 2015012170 A MX2015012170 A MX 2015012170A MX 361984 B MX361984 B MX 361984B
Authority
MX
Mexico
Prior art keywords
hydrochloride salts
antibiotic compound
compounds
compound
formula
Prior art date
Application number
MX2015012170A
Other languages
English (en)
Other versions
MX2015012170A (es
Inventor
Zhang Weijiang
Lee Junning
Cheung Ronnie
Filipov Dimitar
Green Jack
Original Assignee
Theravance Biopharma Antibiotics Ip Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theravance Biopharma Antibiotics Ip Llc filed Critical Theravance Biopharma Antibiotics Ip Llc
Publication of MX2015012170A publication Critical patent/MX2015012170A/es
Publication of MX361984B publication Critical patent/MX361984B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K9/00—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
    • C07K9/006—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence being part of a ring structure
    • C07K9/008—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence being part of a ring structure directly attached to a hetero atom of the saccharide radical, e.g. actaplanin, avoparcin, ristomycin, vancomycin

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Un compuesto de fórmula I: (ver Fórmula) donde x se encuentra dentro del rango entre aproximadamente 1 y aproximadamente 2. También, composiciones farmacéuticas que contienen dichos compuestos; procesos para preparar dichos compuestos; y métodos para usar dichos compuestos, por ejemplo, para tratar una infección bacteriana.
MX2015012170A 2013-03-13 2014-03-06 Sales clorhidrato de un compuesto antibiótico. MX361984B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361779065P 2013-03-13 2013-03-13
PCT/US2014/021064 WO2014158952A1 (en) 2013-03-13 2014-03-06 Hydrochloride salts of an antibiotic compound

Publications (2)

Publication Number Publication Date
MX2015012170A MX2015012170A (es) 2015-11-30
MX361984B true MX361984B (es) 2018-12-19

Family

ID=50483481

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015012170A MX361984B (es) 2013-03-13 2014-03-06 Sales clorhidrato de un compuesto antibiótico.

Country Status (32)

Country Link
US (1) US9161990B2 (es)
EP (1) EP2968446B1 (es)
JP (3) JP6482523B2 (es)
KR (1) KR20150126659A (es)
CN (1) CN105120883B (es)
AR (1) AR095044A1 (es)
AU (1) AU2014241481B9 (es)
BR (1) BR112015022716A2 (es)
CA (1) CA2902720A1 (es)
CY (1) CY1119316T1 (es)
DK (1) DK2968446T3 (es)
EA (1) EA027282B1 (es)
ES (1) ES2633964T3 (es)
GE (2) GEP20186874B (es)
HR (1) HRP20171188T1 (es)
HU (1) HUE033738T2 (es)
IL (1) IL240663A0 (es)
LT (1) LT2968446T (es)
MD (1) MD4599C1 (es)
ME (1) ME02854B (es)
MX (1) MX361984B (es)
PH (1) PH12015502060A1 (es)
PL (1) PL2968446T3 (es)
PT (1) PT2968446T (es)
RS (1) RS56141B1 (es)
SG (1) SG11201507235YA (es)
SI (1) SI2968446T1 (es)
SM (1) SMT201700369T1 (es)
TW (1) TWI608845B (es)
UA (1) UA115086C2 (es)
WO (1) WO2014158952A1 (es)
ZA (1) ZA201506748B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3274327B1 (en) * 2015-03-24 2021-05-05 Wilmar Trading Pte Ltd Polyol esters of metathesized fatty acids and uses thereof

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4434287A (en) * 1975-02-20 1984-02-28 Ciba-Geigy Corporation Cephalosporin derivatives
AR229883A1 (es) 1978-05-26 1983-12-30 Glaxo Group Ltd Procedimiento para la preparacion de antibiotico(6r,7r)-7-((z)-2-(2-aminotiazol-4-il)-2-(2-carboxiprop-2-oxiimino)-acetamido)-3-(1-piridinometil)-cef-3-em-4-carboxilato
US4626534A (en) 1984-07-23 1986-12-02 Eli Lilly And Company Pharmaceutical formulation
DE3801179A1 (de) 1988-01-18 1989-07-27 Hoechst Ag Stabilisierung von cephalosporinderivaten durch trocknung mit einem stabilisator sowie stabile zubereitungsformen mit cephalosporinderivaten
JPH0331449A (ja) 1989-06-27 1991-02-12 Yamaha Corp リードフレーム用Ｆｅ―Ｎｉ合金
JP3129428B2 (ja) 1989-09-30 2001-01-29 エーザイ株式会社 セファロスポリン系薬物を含有する注射用組成物
JPH03193735A (ja) 1989-12-22 1991-08-23 Shionogi & Co Ltd グリコペプチド系抗生物質の安定化組成物
JP4142149B2 (ja) 1997-07-10 2008-08-27 明治製菓株式会社 バンコマイシンの凍結乾燥製剤
TWI335332B (en) * 2001-10-12 2011-01-01 Theravance Inc Cross-linked vancomycin-cephalosporin antibiotics
EP1618114B1 (en) * 2003-04-16 2010-07-14 Sandoz AG Processes for the preparations of cefepime
DE602004024393D1 (de) 2003-05-23 2010-01-14 Theravance Inc Quervernetzte glycopeptid-cephalosporin-antibiotika
US6878868B2 (en) 2003-06-24 2005-04-12 Mcmillan Stacy L. Portable high-hat device
US7067482B2 (en) 2003-07-11 2006-06-27 Theravance, Inc. Cross-linked glycopeptide-cephalosporin antibiotics
TWI342312B (en) 2003-10-22 2011-05-21 Theravance Inc Hydrochloride salts of a glycopeptide phosphonate derivative
EP1656930A1 (en) 2004-11-10 2006-05-17 Basilea Pharmaceutica AG Stabilized freeze-dried formulation for cephalosporin derivatives
US20080103121A1 (en) 2006-10-30 2008-05-01 Gole Dilip J Cephalosporin derivative formulation
FR2932177B1 (fr) 2008-06-06 2012-11-30 Inst Francais Du Petrole Procede d'hydrogenation selective sur un catalyseur contenant de l'or.
JP2010105965A (ja) 2008-10-30 2010-05-13 Taiyo Yakuhin Kogyo Kk バンコマイシン製剤
US8431539B2 (en) 2009-09-17 2013-04-30 Eagle Pharmaceuticals, Inc. Formulations of daptomycin
JP2013511522A (ja) 2009-11-23 2013-04-04 イーグル・ファーマシューティカルズ・インコーポレーテッド ダプトマイシン製剤

Also Published As

Publication number Publication date
TWI608845B (zh) 2017-12-21
EA027282B1 (ru) 2017-07-31
EP2968446B1 (en) 2017-05-03
HK1214524A1 (en) 2016-07-29
AR095044A1 (es) 2015-09-16
US9161990B2 (en) 2015-10-20
CN105120883B (zh) 2017-11-17
SG11201507235YA (en) 2015-10-29
PL2968446T3 (pl) 2017-11-30
AU2014241481B2 (en) 2018-02-01
WO2014158952A1 (en) 2014-10-02
DK2968446T3 (en) 2017-08-28
AU2014241481B9 (en) 2018-02-15
CY1119316T1 (el) 2018-02-14
HRP20171188T1 (hr) 2017-10-06
AU2014241481A1 (en) 2015-10-01
CN105120883A (zh) 2015-12-02
ES2633964T3 (es) 2017-09-26
EA201591697A1 (ru) 2016-02-29
GEP20186874B (en) 2018-06-25
KR20150126659A (ko) 2015-11-12
HUE033738T2 (hu) 2018-01-29
PH12015502060A1 (en) 2016-01-25
ME02854B (me) 2018-04-20
GEAP201813957A (en) 2018-01-25
MX2015012170A (es) 2015-11-30
CA2902720A1 (en) 2014-10-02
EP2968446A1 (en) 2016-01-20
SI2968446T1 (sl) 2017-08-31
MD20150101A2 (ro) 2016-02-29
US20140274877A1 (en) 2014-09-18
LT2968446T (lt) 2017-07-25
UA115086C2 (uk) 2017-09-11
JP2017082016A (ja) 2017-05-18
PT2968446T (pt) 2017-07-27
MD4599B1 (ro) 2018-11-30
JP2018177817A (ja) 2018-11-15
MD4599C1 (ro) 2019-06-30
ZA201506748B (en) 2017-08-30
IL240663A0 (en) 2015-10-29
SMT201700369T1 (it) 2017-09-07
TW201444572A (zh) 2014-12-01
JP2016513642A (ja) 2016-05-16
JP6482523B2 (ja) 2019-03-13
BR112015022716A2 (pt) 2017-07-18
RS56141B1 (sr) 2017-10-31

Similar Documents

Publication Publication Date Title
CR20160564A (es) Dinucleótidos cíclicos como moduladores de sting
CY1120703T1 (el) Ετεροκυκλικες ενωσεις και χρησεις αυτων
MX380394B (es) Compuesto novedoso de bifenilo o una sal del mismo.
CL2015001667A1 (es) Derivados de manosa para tratar infecciones bacterianas.
CO2018000589A2 (es) Oxiesteroles y composiciones farmacéuticas que los contienen
CR20140231A (es) Derivados de ácido benzotiazol-6-il acético y su uso para tratar una infección por vih
MX2017002028A (es) Compuestos de pirrolopirimidina usados como agonista del receptor de tipo toll 7 (tlr7).
UY32174A (es) Nuevos heterociclos sustituidos, composiciones farmaceuticas conteniendolos, procedimientos de preparacion y aplicaciones
MX381417B (es) Inhibidores de glucosidasa.
UY35242A (es) Inhibidores de fosfatidilinositol 3-quinasa
BR112017010354B8 (pt) Compostos de triazolopirimidina, seu uso, e composição farmacêutica
DOP2016000085A (es) Amino-heteroaril-benzamidas como inhibidores de cinasa
MX2016013689A (es) Compuestos 4-amino-imidazoquinolina.
UY35567A (es) ?derivados de 3-((2s,5s)-4-metilen-5-(3- oxopropil)tetrahidrofuran-2-il)propanol, su preparación e intermediarios útiles para la misma?.
CL2013002417A1 (es) Compuestos derivados de fluoropiridinona; composición farmacéutica que los comprende; y su uso en el tratamiento de infecciones bacterianas.
AR103680A1 (es) Inhibidores selectivos de bace1
NZ709986A (en) Pharmaceutical compositions comprising nitroxyl donors
GT201400167A (es) Nuevos derivados de bencil sulfonamida utiles como inhibidores de mogat-2
EA201591362A1 (ru) Соединения и способы лечения бактериальных инфекций
MX2019013291A (es) Compuestos y metodos para tratar infecciones bacterianas.
AR105821A1 (es) COMPUESTOS ÚTILES PARA INHIBIR ROR-g-T
MX373636B (es) Compuestos de azetidiniloxifenilpirrolidina.
MX2018010177A (es) Compuestos de 6,7-dihidro-5h-pirazolo[5,1-b][1,3]oxazina-2-carboxa mida.
DOP2019000119A (es) Moduladores de ROR gamma (RORy)
MX361984B (es) Sales clorhidrato de un compuesto antibiótico.

Legal Events

Date Code Title Description
FG Grant or registration